183 related articles for article (PubMed ID: 28476844)
1. Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
Ji WB; Um JW; Ryu JS; Hong KD; Kim JS; Min BW; Joung SY; Lee JH; Kim YS
Anticancer Res; 2017 May; 37(5):2679-2682. PubMed ID: 28476844
[TBL] [Abstract][Full Text] [Related]
2. In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Yamashita K; Urakami A; Kubozoe T; Ikeda M; Hirabayashi Y; Yamamura M; Iki K; Akiyama T; Matsumoto H; Hirai T; Sadahira Y; Tsunoda T
Int J Clin Oncol; 2005 Oct; 10(5):328-32. PubMed ID: 16247659
[TBL] [Abstract][Full Text] [Related]
3. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Isshi K; Sakuyama T; Gen T; Nakamura Y; Kuroda T; Katuyama T; Maekawa Y
Int J Clin Oncol; 2002 Dec; 7(6):335-42. PubMed ID: 12494248
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
Zaniboni A
J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
[TBL] [Abstract][Full Text] [Related]
7. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
Thirion P; Michiels S; Pignon JP; Buyse M; Braud AC; Carlson RW; O'Connell M; Sargent P; Piedbois P;
J Clin Oncol; 2004 Sep; 22(18):3766-75. PubMed ID: 15365073
[TBL] [Abstract][Full Text] [Related]
8. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
Porschen R; Bermann A; Löffler T; Haack G; Rettig K; Anger Y; Strohmeyer G;
J Clin Oncol; 2001 Mar; 19(6):1787-94. PubMed ID: 11251010
[TBL] [Abstract][Full Text] [Related]
10. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
11. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
Baumgaertner I; Quinaux E; Khalil A; Louvet C; Buyse M; de Gramont A; André T;
Clin Colorectal Cancer; 2010 Apr; 9(2):E5-10. PubMed ID: 20378497
[TBL] [Abstract][Full Text] [Related]
14. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
16. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer.
Yamaue H; Tanimura H; Kono N; Aoki Y; Tabuse K; Uchiyama K; Takifuji K; Iwahashi M; Tani M
Anticancer Res; 2003; 23(3B):2559-64. PubMed ID: 12894541
[TBL] [Abstract][Full Text] [Related]
18. Applicability of histoculture drug response assays in colorectal cancer chemotherapy.
Yoon YS; Kim CW; Roh SA; Cho DH; Kim GP; Hong YS; Kim TW; Kim MB; Kim JC
Anticancer Res; 2012 Aug; 32(8):3581-6. PubMed ID: 22843949
[TBL] [Abstract][Full Text] [Related]
19. Where do we stand with 5-fluorouracil?
Schmoll HJ; Büchele T; Grothey A; Dempke W
Semin Oncol; 1999 Dec; 26(6):589-605. PubMed ID: 10606252
[TBL] [Abstract][Full Text] [Related]
20. Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue.
Kawai K; Watabe S; Matsuda M; Sakamoto K; Kamano T
Int J Gastrointest Cancer; 2005; 35(3):197-203. PubMed ID: 16110121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
